title: Cutting edge: membrane lymphotoxin regulates CD8(+) T cell-mediated intestinal allograft rejection.
abstract: Blocking the CD28/B7 and/or CD154/CD40 costimulatory pathways promotes long-term allograft survival in many transplant models where CD4(+) T cells are necessary for rejection. When CD8(+) T cells are sufficient to mediate rejection, these approaches fail, resulting in costimulation blockade-resistant rejection. To address this problem we examined the role of lymphotoxin-related molecules in CD8(+) T cell-mediated rejection of murine intestinal allografts. Targeting membrane lymphotoxin by means of a fusion protein, mAb, or genetic mutation inhibited rejection of intestinal allografts by CD8(+) T cells. This effect was associated with decreased monokine induced by IFN-gamma (Mig) and secondary lymphoid chemokine (SLC) gene expression within allografts and spleens respectively. Blocking membrane lymphotoxin did not inhibit rejection mediated by CD4(+) T cells. Combining disruption of membrane lymphotoxin and treatment with CTLA4-Ig inhibited rejection in wild-type mice. These data demonstrate that membrane lymphotoxin is an important regulatory molecule for CD8(+) T cells mediating rejection and suggest a strategy to avoid costimulation blockade-resistant rejection.
authors.affiliation: Emory Transplant Center and Department of Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA.
authors.forename: Z
authors.initials: Z
authors.lastname: Guo
authors.forename: J
authors.initials: J
authors.lastname: Wang
authors.forename: L
authors.initials: L
authors.lastname: Meng
authors.forename: Q
authors.initials: Q
authors.lastname: Wu
authors.forename: O
authors.initials: O
authors.lastname: Kim
authors.forename: J
authors.initials: J
authors.lastname: Hart
authors.forename: G
authors.initials: G
authors.lastname: He
authors.forename: P
authors.initials: P
authors.lastname: Zhou
authors.forename: J R
authors.initials: JR
authors.lastname: Thistlethwaite
authors.forename: M L
authors.initials: ML
authors.lastname: Alegre
authors.forename: Y X
authors.initials: YX
authors.lastname: Fu
authors.forename: K A
authors.initials: KA
authors.lastname: Newell
mesh_terms: D000069594:Abatacept; D000818:Animals; D015703:Antigens, CD; D000943:Antigens, Differentiation / Q000494:pharmacology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D060908:CTLA-4 Antigen; D006084:Graft Rejection; D018796:Immunoconjugates; D007422:Intestines / Q000637:transplantation*; D008233:Lymphotoxin-alpha / Q000502:physiology*; D008565:Membrane Proteins / Q000502:physiology; D051379:Mice; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D018124:Receptors, Tumor Necrosis Factor / Q000502:physiology; D053240:Receptors, Tumor Necrosis Factor, Member 14; D011991:Receptors, Virus / Q000502:physiology; D014184:Transplantation, Homologous; D053326:Tumor Necrosis Factor Ligand Superfamily Member 14; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
chemical_list: D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556707:Ctla4 protein, mouse; D018796:Immunoconjugates; D008233:Lymphotoxin-alpha; D008565:Membrane Proteins; D018124:Receptors, Tumor Necrosis Factor; D053240:Receptors, Tumor Necrosis Factor, Member 14; D011991:Receptors, Virus; C506029:Tnfrsf14 protein, mouse; C505915:Tnfsf14 protein, mouse; D053326:Tumor Necrosis Factor Ligand Superfamily Member 14; D014409:Tumor Necrosis Factor-alpha; D000069594:Abatacept